- Satavaptan
Drugbox
IUPAC_name = N-("t"-butyl)-4-((cis-5'-ethoxy-4-(2-(morpholin-4-yl)ethoxy))-2'-oxo-1',2'-dihydrospiro(cyclohexane-1:3'-indole)-1'-yl)sulfonyl)-3-methoxybenzamide
width= 280
CAS_number= 185913-78-4
ATC_prefix=
ATC_suffix=
PubChem= 9810773
DrugBank=
C=33 | H=45 | N=3 | O=8 | S=1
molecular_weight = 643.789
bioavailability=
metabolism =
elimination_half-life=
excretion =
pregnancy_category =
legal_status =
routes_of_administration=Satavaptan (INN; codenamed SR121463, planned tradename Aquilda) is a vasopressin-2 receptor antagonistcite journal |author=Soupart A, Gross P, Legros JJ, "et al" |title=Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist |journal=Clin J Am Soc Nephrol |volume=1 |issue=6 |pages=1154–60 |year=2006 |month=November |pmid=17699341 |doi=10.2215/CJN.00160106 |url=] undergoing research for the treatment of
hyponatremia . It is also being studied for the treatment ofascites .cite journal |author=Ginès P, Wong F, Watson H, Milutinovic S, Ruiz Del Arbol L, Olteanu D |title=Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial |journal=Hepatology |volume= |issue= |pages= |year=2008 |month=February |pmid=18508290 |doi=10.1002/hep.22293 |url=]It was developed by
Sanofi-Aventis . As of 2008, it is under regulatory review in theEuropean Union .ee also
*
Conivaptan
*Mozavaptan
*Tolvaptan References
Wikimedia Foundation. 2010.
